Chad Bello
Directeur Financier/CFO chez Prolexys Pharmaceuticals, Inc.
Profil
Chad Bello is Finance Director for Prolexys Pharmaceuticals, Inc. Prior to joining Prolexys in January, 2002 he was a Senior Accountant for Porter & Porter.
He received a Bachelor's degree in Accounting from the University of Utah and an MBA from Westminster College.
Postes actifs de Chad Bello
| Sociétés | Poste | Début |
|---|---|---|
Prolexys Pharmaceuticals, Inc.
 Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Directeur Financier/CFO | 01/01/2002 |
Anciens postes connus de Chad Bello
| Sociétés | Poste | Fin |
|---|---|---|
Porter & Associates
 Porter & Associates Publishing: Books/MagazinesConsumer Services Part of Ascend Learning LLC, Porter & Associates is a publisher of pocket guides for healthcare professionals and institutions. Porter & Associates was acquired by Jones & Bartlett Publishers, Inc. on April 19, 2006. | Comptroller/Controller/Auditor | - |
Formation de Chad Bello
| University of Utah | Undergraduate Degree |
| Westminster College (Utah) | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Porter & Associates
Porter & Associates Publishing: Books/MagazinesConsumer Services Part of Ascend Learning LLC, Porter & Associates is a publisher of pocket guides for healthcare professionals and institutions. Porter & Associates was acquired by Jones & Bartlett Publishers, Inc. on April 19, 2006. | Consumer Services |
